Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (19)

2024

  1. Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)

    European Journal of Heart Failure

  2. Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial

    Journal of the American Heart Association, Vol. 13, Núm. 19, pp. e035460

  3. Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity

    European Journal of Heart Failure

2023

  1. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

    Clinical and Translational Oncology, Vol. 25, Núm. 11, pp. 3073-3085

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. Analysis of the management of ST-segment elevation myocardial infarction in Spain. Results from the ACI-SEC Infarction Code Registry

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 669-680

  2. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  3. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

  4. Short-term mortality differs between men and women according to the presence of previous cardiovascular disease: Insights from a nationwide STEMI cohort

    International Journal of Cardiology, Vol. 367, pp. 90-98

2021

  1. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients

    EuroIntervention, Vol. 16, Núm. 17, pp. 1426-1433

  2. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity

    Cardiovascular research, Vol. 117, Núm. 4, pp. 1132-1143

2020

  1. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

  2. Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy

    Revista Espanola de Cardiologia, Vol. 73, Núm. 3, pp. 268-269

2019

  1. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity

    Journal of the American College of Cardiology, Vol. 73, Núm. 7, pp. 779-791

2018

  1. Response by Fernández-Jiménez et al to Letters Regarding Article, "Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage"

    Circulation

2017

  1. Dynamic edematous response of the human heart to myocardial infarction: Implications for assessing myocardial area at risk and salvage

    Circulation, Vol. 136, Núm. 14, pp. 1288-1300

  2. Effect of Ischemia Duration and Protective Interventions on the Temporal Dynamics of Tissue Composition after Myocardial Infarction

    Circulation Research, Vol. 121, Núm. 4, pp. 439-450

2016

  1. Data from acellular human heart matrix

    Data in Brief

2015

  1. Acellular human heart matrix: A critical step toward whole heart grafts

    Biomaterials, Vol. 61, pp. 279-289